表紙:CAR-T細胞療法の世界市場 - 市場規模、予測、治験、動向(2024年)
市場調査レポート
商品コード
1493841

CAR-T細胞療法の世界市場 - 市場規模、予測、治験、動向(2024年)

Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2024

出版日: | 発行: BioInformant | ページ情報: 英文 329 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.16円
CAR-T細胞療法の世界市場 - 市場規模、予測、治験、動向(2024年)
出版日: 2024年06月12日
発行: BioInformant
ページ情報: 英文 329 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

CAR-T細胞療法は、がん患者にとって極めて有望な治療法です。これは免疫療法の一種で、医師が免疫細胞を集め、実験室で改変し、がん細胞を容易に認識して殺す力を与えるものです。患者に注入されると、細胞は増殖し、"生きた薬"として体内に留まります。

T細胞はCAR-T細胞療法のバックボーンを形成します。T細胞は私たちの免疫システムの主力であり、免疫反応を指揮し、病原体に感染した細胞を殺すという重要な役割を担っています。CAR-T細胞療法では、患者から血液を採取し、T細胞を分離します。その後、実験室で、武装解除されたウイルスを用いて、T細胞の表面にキメラ抗原受容体(CAR)を産生するように遺伝子操作します。このCARを患者に注入すると、T細胞はがん細胞上の抗原を認識して結合し、がん細胞を破壊します。

2017年から今日までに、9つのCAR-T製品が商業化に至り、この数は2032年までに二桁に達すると予測されています。このうち6製品は米国FDAが承認したCAR-T細胞療法で、それぞれ他の主要ヘルスケア市場でも承認を受けています。

さらに、2つのCAR-T療法が中国国家医薬品監督管理局(NMPA)よりRelma-celとYuanruidaの承認を、1つのCAR-T細胞療法がインド中央医薬品標準管理機関(CDSCO)よりNexCAR19の承認を取得しています。

10億米ドル規模のCAR-T細胞療法市場は、初期のCAR-T療法が数種類の血液がんに対して顕著な有効性を示したことなしには実現しなかったと考えられます。CAR-T細胞療法の今後の見通しとしては、固形がんとの闘いに応用することです。市販されている9つのCAR-T細胞療法製品のすべてと、現在進行中の臨床試験のほぼ4分の3(75%)は、自家治療法を利用しています。したがって、同種CAR-T細胞療法の開発は、重要な市場機会を開くことになります。

当レポートでは、世界のCAR-T細胞療法市場について調査し、市場の動向と製品別、地域別、適応症別の2032年までの市場予測、製品概要、治験動向、市場の機会、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 調査概要

第2章 CAR-T細胞療法:技術開発

  • CAR-T細胞
  • CAR-T開発の進化
  • 造血悪性細胞に存在する抗原
  • T細胞に受容体遺伝子を挿入するためのツール
  • T細胞をCAR-T細胞に変換する
  • 市場で入手可能な8つのCAR-T療法:概要
  • CAR-T治療に伴う毒性

第3章 将来のCAR-T療法の戦略

第4章 CAR-T開発における主な出来事、1989年~2024年

第5章 CAR-T細胞のスケーラブルな製造

  • 臨床規模の自己CAR-T療法の製造プロセス
  • CAR-T細胞製造プラットフォームの進化

第6章 CAR-T標的抗原

  • 血液がんにおけるCAR-T標的抗原
  • CAR-Tは固形腫瘍上の抗原を標的とする
  • 臨床試験でCAR-T細胞が標的とする一般的な抗原

第7章 CAR-T特許の情勢

第8章 CAR-T臨床情勢

第9章 CAR-T科学論文

第10章 CAR-Tの資金調達の情勢

第11章 CAR-T治療の費用と償還

  • 新しい支払いモデル
  • 米国におけるCAR-T療法の償還
  • 欧州におけるCAR-T療法のコスト
  • アジアにおけるCAR-T療法の費用と償還

第12章 CAR-Tが治療する血液がん

  • 急性リンパ性白血病(ALL)
  • びまん性大細胞型B細胞リンパ腫(DLBCL)
  • マントル細胞リンパ腫(MCL)
  • 多発性骨髄腫(MM)
  • 濾胞性リンパ腫
  • 血液がん治療の莫大なコスト

第13章 市場分析

  • CAR-T細胞療法の普及、2017年~2023年
  • 世界のCAR-T細胞療法製品の市場予測、2024年~2032年
  • 血液がんにおけるCAR-T療法の課題と機会

第14章 CAR-T細胞療法市場参入企業の概要

  • 2seventy bio
  • Abintus Bio, Inc.
  • AffyImmune Therapeutics, Inc.
  • Aleta BioTherapeutics
  • Allogene Therapeutics
  • Anixa Biosciences, Inc.
  • Arbele, Ltd.
  • Arcellx
  • Atara Biotherapeutics
  • Aurora BioPharma
  • Autolus Therapeutics plc
  • AvenCell Europe GmbH
  • Beam Therapeutics, Inc.
  • Bellicum Pharmaceuticals
  • BioNTech
  • Biosceptre
  • Bluebird bio
  • Bristol Myers Squibb/Celgene Corporation
  • Cabaletta Bio
  • Carina Biotech
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • CARTherics Pty Ltd.
  • CASI Pharmaceuticals
  • Cellectis
  • Celularity, Inc.
  • Celyad Oncology
  • CRISPR Therapeutics
  • Curocell, Inc.
  • DiaCarta
  • Elicera Therapeutics AB
  • EXUMA Biotech
  • Fate Therapeutics
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Gracell Biotechnologies
  • IASO Biotherapeutics
  • ImmPACT Bio
  • Immuneel Therapeutics, Pvt., Ltd.
  • ImmunoACT
  • Interius BioTherapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • Kite Pharma (Gilead)
  • Kyverna Therapeutics
  • Legend Biotech
  • Leucid Bio
  • Luminary Therapeutics, Inc.
  • Lyell Immunopharma, Inc.
  • March Biosciences
  • MaxCyte, Inc.
  • Minerva Biotechnologies Corporation
  • Mustang Bio
  • Noile-Immune Biotech
  • Novartis AG
  • Oncternal Therapeutics
  • Oxford Biomedica plc
  • PeproMene Bio, Inc.
  • Poseida Therapeutics, Inc.
  • Precigen, Inc.
  • Prescient Therapeutics
  • ProMab Biotechnologies, Inc.
  • SOTIO Biotech BV
  • Syngene International, Ltd.
  • Synthekine
  • TC BioPharm
  • T-CURX
  • Umoja Biopharma
  • ViTToria Biotherapeutics
  • Vor Biopharma
  • Wugen
  • WuXi Advanced Therapies
  • Xenetic Biosciences
  • Xyphos Biosciences, Inc.

図表索引

目次

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. Once infused into the patient, these CARs enable the T-cells to recognize and attach to an antigen on the cancer cell, leading to its destruction.

Between 2017 and today, nine CAR-T products reached commercialization, and this number is estimated to reach double-digits by 2032. Of these, six are U.S.FDA-approved CAR-T cell therapies, each of which have received approvals in other major healthcare markets as well.

The six U.S. FDA approved products include:

  • 1. Kymriah (tisagenlecleucel)
  • 2. Yescarta (axicabtagene ciloleucel)
  • 3. Tecartus (brexucabtagene autoleucel)
  • 4. Breyanzi (lisocabtagene maraleucel)
  • 5. Abecma (idecabtagene vicleucel)
  • 6. Carvykti (Ciltacabtagene autoleucel)

In addition, two CAR-T therapies have received approval from the Chinese National Medical Products Administration (NMPA), Relma-cel and Yuanruida, and one CAR-T cell therapy has received approval from the Indian Central Drugs Standard Control Organisation (CDSCO), NexCAR19.

These historic approvals demonstrate that the CAR-T market has arrived and is taking the biotech industry by storm. M&A activity has been particularly aggressive, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead's acquisition of Kite Pharma for $11.9 billion also made waves, as did other transactions, such as Astellas Pharma's acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.

The billion-dollar CAR-T cell therapy market would not have been possible without the remarkable efficacy of the early CAR-T therapies in treating several types of blood cancers. The next frontier for CAR-T cell therapies will be to apply them in the fight against solid tumors. All of the nine marketed CAR-T cell therapy products and nearly three-quarters (75%) of the ongoing clinical trials utilize an autologous treatment approach. Thus, the development of allogeneic CAR-T cell therapies will open critical market opportunities.

Another key issue is the "vein-to-vein" time or the time that elapses between apheresis and product delivery. Thus, CAR-T therapies are usually recommended for the end-stage patients who have exhausted all other treatment options. Another challenge encountered by CAR-T therapies is the reimbursement issues across the U.S. and Europe.

For the continued progress of CAR-T cell therapies, the industry is trying to mitigate these challenges. Several CAR-T players have started to use efficient gene-transfer tools to impregnate T cells with CARs, and there are numerous examples of partnerships to develop CRISPR and electroporation technologies to modify T cells. Some companies also use "on-off" switches that can turn off CAR-T cells to prevent toxicity. Thus far, the goal of achieving success with solid tumors remains elusive with clinical trials producing a low response rate. Thus, ongoing efforts within the CAR-T sector are focused on discovering effective solid tumor-specific antigens.

The purpose of this report is to describe the current state of CAR-T cell therapies, as well as the future of the CAR-T industry landscape at large. Importantly, it describes details of the CAR-T cell therapy products approved to date, as well as late-stage CAR-T clinical trials that could lead to near-term market approvals. Ranging from small start-ups to billion-dollar companies, CAR-T companies are now proliferating in all healthcare markets worldwide.

Key questions answered in this report include:

  • How many automated manufacturing systems are available within the global market?
  • What are the most targeted antigens for liquid and solid cancers?
  • What are anticipated developments within the CAR-T sector? What commercial opportunities and patient outcomes will they unlock?
  • How many CAR-T-related patent publications and granted patents were issued from 2012 to present?
  • Which two countries have the largest number of CAR-T patents?
  • Which 20 companies have filed the largest number of CAR-T patents?
  • Who are the top 20 CAR-T patent inventors?
  • How many clinical trials were registered between 2003 and present?
  • Which biomarker antigens dominate in the CAR-T clinical trial landscape?
  • Which are the most common indications addressed by clinical trials in the U.S. and China?
  • Who are the U.S., Chinese, and European companies involved in CAR-T-related clinical trials?
  • How many deals have been signed within the CAR-T sector within the past year?
  • What are promising CAR-T candidates that could soon reach commercialization?
  • How are CAR-T therapies reimbursed within the U.S. and Europe?
  • What is the current market size for CAR-T cell therapies by Geography, Product, and Indication?
  • What are the future market forecasts for CAR-T cell therapies by Geography, Product, and Indication?
  • What are the barriers, risks, and opportunities for growth within the global CAR-T industry?
  • Who are the major companies that are developing CAR-T cell therapies, what are their core technologies, and what products do they have under development?

This 329-page market report reveals:

  • Global CAR-T Cell Therapy Market Size, with Segmentation by Product, Geography, and Indication, including Future Market Size Forecasts through 2032
  • Detailed Coverage of the Approved CAR-T Products, including Regulatory Approvals, Pricing, Reimbursement, and Degree of Market Penetration
  • Clinical Trial Activity by Type, Geography, Phase, and Sponsor
  • Comprehensive CAR-T Patent Analysis, including Top Inventors, Patent Holders, Patent Types, Geographies, and Most Cited Patents
  • CAR-T Industry Mergers and Acquisitions, IPOs, and Financing Events
  • Strategic Partnerships, Alliances, and Co-commercialization Agreements within the CAR-T sector
  • Market Trends, Future Directions, and Emerging Opportunities
  • Profiles of Leading CAR-T Competitors Composing the Global Marketplace
  • And Much More

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.2. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction

2. CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT

  • 2.1. CAR-T cell
  • 2.2. Evolution of CAR-T Development
    • 2.2.1. The CAR-T cell Family
      • 2.2.1.1. First Generation CARs
      • 2.2.1.2. The Second Generation CARs
      • 2.2.1.3. Third Generation CARs
      • 2.2.1.4. Fourth Generation CARs
      • 2.2.1.5. Fifth Generation CARs
      • 2.2.1.6. CAR Constructs in the FDA Approved CAR-T Cell Products
  • 2.3. Antigens Present on Hematological Malignant Cells
  • 2.4. Tools for Inserting Receptor Genes into T Cells
  • 2.5. Transforming T Cells into CAR-T Cells
  • 2.6. The Eight CAR-T Therapies Available in the Market: A Brief Overview
    • 2.6.1. Kymriah (tisagenlecleucel)
      • 2.6.1.1. Indication
      • 2.6.1.2. Product Description & Machanism of Action
      • 2.6.1.3. Manufacturing
      • 2.6.1.4. Dosage Composition
      • 2.6.1.5. Approval History
      • 2.6.1.6. Market
      • 2.6.1.7. Competition
    • 2.6.2. Yescarta (axicabtagene ciloleucel)
      • 2.6.2.1. Indication
      • 2.6.2.2. Product Description & Mechanism of Action
      • 2.6.2.3. Manufacturing Process of Yescarta
      • 2.6.2.4. Dosage Composition
      • 2.6.2.5. Approval History
      • 2.6.2.7. Sales Revenues
      • 2.6.2.8. Competitors
    • 2.6.3. Tecartus (brexucabtagene autoleucel)
      • 2.6.3.1. Indication
      • 2.6.3.2. Product Description & Mechanism of Action
      • 2.6.3.3. Tecartus Manufacturing Process
      • 2.6.3.4. Dosage Composition
      • 2.6.3.5. Approval History
      • 2.6.3.6. Sales Revenues
      • 2.6.3.7. Competitors
    • 2.6.4. Carvykti (ciltacabtagene autoleucel)
      • 2.6.4.1. Indication
      • 2.6.4.2. Product Description & Mechanism of Action
      • 2.6.4.3. Manufacturing Process of Carvykti
      • 2.6.4.4. Dosage & Composition
      • 2.6.4.5. Approval History
      • 2.6.4.6. Sales Revenues
      • 2.6.4.7. Competition
    • 2.6.5. Abecma (idecabtagene vicleucel)
      • 2.6.5.1. Indication
      • 2.6.5.2. Product Description and Mechanism of Action
      • 2.6.5.3. Manufacturing of Abecma
      • 2.6.5.4. Dosage & Composition
      • 2.6.5.5. Approval History
      • 2.6.5.6. Sales Revenues
      • 2.6.5.7. Competitors
    • 2.6.6. Breyanzi (lisocabtagene maraleucel)
      • 2.6.6.1. Indication
      • 2.6.6.2. Product Description & Mechanism of Action
      • 2.6.6.3. Manufacturing
      • 2.6.6.4. Breyanzi Dosage & Composition
      • 2.6.6.5. Approval History
      • 2.6.6.6. Sales Revenues
    • 2.6.7. Relma-cel (relmacabtagene autoleucel)
    • 2.6.8. NexCAR19 (Actalycabtagene autoleucel)
    • 2.6.9. Yuanruida (inaticabtagene autoleucel; CNCT19)
  • 2.7. Toxicities Associated with CAR-T Treatment

3. STRATEGIES FOR FUTURE CAR-T THERAPIES

  • 3.1. Switchable CARs (sCARs)
  • 3.2. Suicide Genes to Destroy CAR-T Cells in vivo
  • 3.3. Transient Transfection
  • 3.4. Affinity-Tuned CARs
  • 3.5. Armored CARs
  • 3.6. Shifts from Liquid Cancers to Solid Tumors
  • 3.7. Focus on Shortening Hospital Stay
  • 3.8. Focus on Discovering New Antigens
  • 3.9. Shifting from Autologous to Allogeneic CAR-T Therapies
  • 3.10. CAR-T for the Masses
  • 3.11. New in vivo CAR-T Approaches
  • 3.12. Combination with mRNA Vaccine
  • 3.13. Combination with Oncolytic Virus

4. MAJOR EVENTS DURING THE DEVELOPMENT OF CAR-T, 1989-2024

  • 4.1. CAR-T Development Timeline
  • 4.2. Top Ten Milestones Crossed by CAR-T Therapy
    • 4.2.1. First Pediatric Patient to Receive CAR-T Therapy
    • 4.2.2. CAR-T Granted Breakthrough Therapy Designation
    • 4.2.3. The Beginning of CAR-T Development to Combat Solid Cancers
    • 4.2.4. First CRISPR CAR-T Built
    • 4.2.5. The First Two CAR-T Approvals by FDA
    • 4.2.6. The First Two CAR-T Approvals by EMA
    • 4.2.7. Approval of Tecartus, Breyanzi and Abecma
    • 4.2.8. NMPA Approval of Relma-cel (Carteyva)
    • 4.2.9. Approval of Carvykti
    • 4.2.10. Approval of NexCAR19 (actalycabtagene autoleucel)
    • 4.2.11. Approval of Yuanruida (inaticabtagene autoleucel)
  • 4.3. Current Status of CAR-T Therapy Products
  • 4.4. The Upcoming CAR-T Stars
    • 4.4.1. ALLO-501
    • 4.4.2. CTX-110
    • 4.4.3. UCART19
    • 4.4.4. AUT01
    • 4.4.5. JCARH125
    • 4.4.6. PBCAR20A
    • 4.4.7. UCART123
    • 4.4.8. PRGN-3006
    • 4.4.9. UCART22
    • 4.4.10. UCARTCS1
  • 4.5. Cancer Population Addressed by CAR-T Therapy
  • 4.6. Advantages of CAR-T Cell Therapy
  • 4.7. Disadvantages of CAR-T Cell Therapy

5. SCALABLE MANUFACTURING OF CAR-T CELLS

  • 5.1. The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies
  • 5.2. The Evolution of CAR-T Cell Manufacturing Platforms
    • 5.2.1. Open vs. Closed Systems
    • 5.2.2. Manual Processing vs. Automation
    • 5.2.3. Autologous vs. Allogeneic CAR-T Manufacturing
    • 5.2.4. Operating Expenses in Allogeneic CAR-T Manufacturing
    • 5.2.5. Operating Expenses in Allogeneic CAR-T Manufacturing

6. CAR-T TARGET ANTIGENS

  • 6.1. CAR-T Target Antigens in Hematological Cancers
  • 6.2. CAR-T Target Antigens on Solid Tumors
  • 6.3. Common Antigens Targeted by CAR-T Cells in Clinical Trials
    • 6.3.1. Cluster Differentiation 19 (CD19)
    • 6.3.2. Mesothelin
    • 6.3.3. Beta Cell Maturation Agent (BCMA)
    • 6.3.4. GD2
    • 6.3.5. Glypican-3 (GPC3)
    • 6.3.6. Cluster Differentiation-22 (CD22)

7. CAR-T PATENT LANDSCAPE

  • 7.1. Geographical Distribution of CAR-T Patents
  • 7.2. Top Ten Applicants of CAR-T Patents
  • 7.3. Top Ten Inventors of CAR-T Patents
  • 7.4. Top Ten Owners of CAR-T Patents
  • 7.5. Legal Status of CAR-T Patents

8. CAR-T CLINICAL TRIAL LANDSCAPE

  • 8.1. Most Addressed Indications in Clinical Trials
  • 8.2. Current Focus of Ongoing Clinical Trials
  • 8.3. Clinical Trial by Country
  • 8.4. Phase of Studies
  • 8.5. CAR-T Clinical Trials by Funding Type
  • 8.6. Types of Hematological Malignancies Addressed in Clinical Trials
  • 8.7. Simultaneous Targets by one CAR-T
  • 8.8. CAR-T Generation Types used in Clinical Trials
  • 8.9. CAR-T Clinical Trials Focusing on Solid Cancers
  • 8.10. Distribution of CAR-T Trials by Type of SeFv Used
  • 8.11. Distribution of CAR-T Trials by Type of Vectors Used
  • 8.12. Geographical Distribution of CAR-T Studies in Solid Tumors
    • 8.12.1. CAR-T Solid Tumor Clinical Trials by Phase of Study
    • 8.12.2. Funding Types in CAR-T Solid Tumor Clinical Trials
    • 8.12.3. Solid Tumor Types in Clinical Trials
  • 8.13. CAR-T Targeted Biomarkers in Clinical Trials
    • 8.13.1. CAR-T Targeted Indications in the U.S. Clinical Trials
    • 8.13.2. Indications Addressed by CAR-T Clinical Trials in China
    • 8.13.3. Liquid Cancers vs. Solid Cancers in CAR-T Clinical Trials
    • 8.13.4. CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
    • 8.13.5. CAR-T Clinical Trial Sponsor Companies and Institutions in China
    • 8.13.6. CAR-T Trial Sponsor Companies and Institutions in Other Countries
  • 8.14. Improved CAR-T Constructs in Clinical Trials
    • 8.14.1. CAR-T with PD1Fc
    • 8.14.2. CAR-T with Truncated EFGR
    • 8.14.3. CAR-T with IL7 and CCL 19
    • 8.14.4. CAR-T with PD1/CD28 Switch Receptor
    • 8.14.5. CAR-T with PD1 shRNA Expressing Cassette
    • 8.14.6. CAR-T with CTLA-4/PD-1 Antibody
    • 8.14.7. CAR-T with PD-1 Antibodies

9. PUBLISHED CAR-T SCIENTIFIC PAPERS IN PUBMED.GOV

  • 9.1. PubMed.gov Papers on Autologous and Allogeneic CAR-T Therapies
  • 9.2. PubMed.gov Papers on CAR-T for Liquid vs. Solid Cancers, 2013-March 2024
  • 9.3. PubMed Papers on the Five Generation of CARs
  • 9.4. NIH Funding for CAR-T Research

10. CAR-T FUNDING LANDSCAPE

  • 10.1. Venture Capital Funding in CAR-T Sector, 2014-March 2024
    • 10.1.1. Venture Capital Funding for CAR-T Companies by Year, 2014-March 2024
  • 10.2. IPO Funding in Invested in CAR-T Companies, 2014-March 2024
  • 10.3. CAR-T Licensing Deals
  • 10.4. CAR-T Collaboration Deals
  • 10.5. CAR-T Merger and Acquisition (M&A) Deals, 2015-March 2024
  • 10.6. Overview of CAR-T Funding

11. COST OF CAR-T TREATMENT AND REIMBURSEMENT

  • 11.1. New Payment Models
    • 11.1.1. List Price of approved CAR-Ts
    • 11.1.2. Component Cost in addition to Treatment Acquisition Cost
    • 11.1.3. Adverse Event Costs (AEs)
  • 11.2. Reimbursement in the U.S. for CAR-T Therapy
    • 11.2.1. Policy Changes for FY 2024
  • 11.3. Cost of CAR-T Therapies in Europe
    • 11.3.1. Cost Components and Resource Use
    • 11.3.2. Average Total Component Costs for CAR-T Therapy in Former EU-5 and NL
    • 11.3.3. Reimbursement for CAR-T Therapies in Europe
    • 11.3.4. Innovative Reimbursement Schemes in Europe
  • 11.4. Cost & Reimbursement for CAR-T Therapy in Asia
    • 11.4.1. Cost & Reimbursement for CAR-T in Japan
    • 11.4.2. Cost & Reimbursement for CAR-T Therapy in South Korea
    • 11.4.3. Cost & Reimbursement for CAR-T Therapy in Malaysia
    • 11.4.4. Cost & Reimbursement for CAR-T Therapy in Singapore
    • 11.4.5. Cost & Reimbursement for CAR-T Therapy in China
    • 11.4.6. Cost of CAR-T Therapy in India

12. BLOOD CANCERS ADDRESSED BY CAR-T

  • 12.1. Acute Lymphoblastic Leukemia (ALL)
    • 12.1.1. Available Therapies
  • 12.2. Diffuse Large B-Cell Lymphoma (DLBCL)
    • 12.2.1. Available Therapies
  • 12.3. Mantle Cell Lymphoma (MCL)
    • 12.3.1. Available Therapies
  • 12.4. Multiple Myeloma (MM)
    • 12.4.1. Available Therapies
  • 12.5. Follicular Lymphoma
    • 12.5.1. Available Therapies
  • 12.6. The Staggering Cost of Blood Cancer Therapies

13. MARKET ANALYSIS

  • 13.1. Uptake of CAR-T Cell Therapy, 2017-2023
    • 13.1.1. Current Global Market for CAR-T Cell Therapy by Product
  • 13.2. Estimated Global Market for CAR-T Cell Therapy Products, 2024-2032
    • 13.2.1. Global Market for CAR-T Therapy by Geography
    • 13.2.2. Global Market for CAR-T Therapy by Indication
  • 13.3. Challenges & Opportunities for CAR-T Therapies in Blood Cancers
    • 13.3.1. Barriers to Access
    • 13.3.2. Targets other than CD19
    • 13.3.3. Resistance for CAR-T Therapy
    • 13.3.4. Manufacturing Time
    • 13.3.5. Autologous vs. Allogeneic CAR-Ts

14. CAR-T COMPNIES: AN OVERVIEW

  • 14.1. 2seventy bio
    • 14.1.1. Abecma (idecabtagene vicleucel)
  • 14.2. Abintus Bio, Inc.
  • 14.3. AffyImmune Therapeutics, Inc.
    • 14.3.1. Affinity-Tuned CARs
      • 14.3.1.1. ICAM-1: AffyImmune's Target Antigen
      • 14.3.1.2. Targeted Indication
  • 14.4. Aleta BioTherapeutics
    • 14.4.1. Aleta's CAR-T Engager Pipeline
  • 14.5. Allogene Therapeutics
    • 14.5.1. AlloCAR-T
      • 14.5.1.1. Manufacturing of AlloCAR-T
  • 14.6. Anixa Biosciences, Inc.
  • 14.7. Arbele, Ltd.
    • 14.7.1. Advanced Cell Therapy
  • 14.8. Arcellx
    • 14.8.1. D-Domain Technology
    • 14.8.2. ddCAR Platform
    • 14.8.3. ARC-SparX Platform
  • 14.9. Atara Biotherapeutics
    • 14.9.1. Technology
    • 14.9.2. Allogeneic CAR-T Programs
  • 14.10. Aurora BioPharma
    • 14.10.1. HER2 Platform
  • 14.11. Autolus Therapeutics plc
    • 14.11.1. Technology
    • 14.11.2. CAR-T Cell Production
    • 14.11.3. Manufacturing
    • 14.11.4. Therapies in Development
      • 14.11.4.1. obe-cel
  • 14.12. AvenCell Europe GmbH
    • 14.12.1. Universal Switchable CAR
    • 14.12.2. Allogeneic Platform
    • 14.12.3. Clinical & Preclinical Pipeline Overview
  • 14.13. Beam Therapeutics, Inc.
    • 14.13.1. BEAM-201
  • 14.14. Bellicum Pharmaceuticals
    • 14.14.1. GoCAR Technology
    • 14.14.2. CaspaCIDe Safety Switch
  • 14.15. BioNTech
    • 14.15.1. BioNtech's Engineered Cell Therapies
    • 14.15.2. BN211
    • 14.15.3. BN212
  • 14.16. Biosceptre
    • 14.16.1. Biosceptre's Unique Target nf2X7
    • 14.16.2. BRiDGECAR Program
  • 14.17. Bluebird bio
    • 14.17.1. Blebird bio's CAR-T Collaborations
    • 14.17.2. Collaboration with BMS
    • 14.17.3. Collaboration with TC BioPharm
    • 14.17.4. Collaboration with Inhibrx
    • 14.17.5. Collaboration with PsiOxus
  • 14.18. Bristol Myers Squibb/Celgene Corporation
    • 14.18.1. Products
      • 14.18.1.1. Abecma (idecabtagene vicleucel)
      • 14.18.1.2. Breyanzi (lisocabtagene maraleucel)
  • 14.19. Cabaletta Bio
    • 14.19.1. CABA Platform
    • 14.19.2. Cabaletta's Pipeline
  • 14.20. Carina Biotech
  • 14.21. CARsgen Therapeutics
    • 14.21.1. CycloCAR-T
    • 14.21.2. THANK-uCAR
    • 14.21.3. LADAR
  • 14.22. Cartesian Therapeutics
    • 14.22.1. mRNA CAR-T Cell Program (RNA Armory)
    • 14.22.2. Pipeline
  • 14.23. CARTherics Pty Ltd.
    • 14.23.1. Autologous CAR-T Cells
  • 14.24. CASI Pharmaceuticals
    • 14.24.1. Yuanruida (inaticabtagene autoleucel; CNCT19)
  • 14.25. Cellectis
    • 14.25.1. TAL nucleases, or TALEN
    • 14.25.2. Gene Editing
    • 14.25.3. PulseAgile Technology
    • 14.25.4. Main Product Candidates
  • 14.26. Celularity, Inc.
    • 14.26.1. P CAR-T
  • 14.27. Celyad Oncology
    • 14.27.1. NKG2D-Based CAR-T Cells
    • 14.27.2. Multispecific CAR
    • 14.27.3. Short Hairpin RNA-based Platform
    • 14.27.4. CAR-T Therapy Development Services
    • 14.27.5. Biomarker Identification and Selection
    • 14.27.6. scFv Generation
    • 14.27.7. CAR-T Gene Packaging and Delivery
    • 14.27.8. Virus Testing Servive
    • 14.27.9. CAR Cell in vitro Assay Service
    • 14.27.10. CAR-T Preclinical in vivo Assay
    • 14.27.11. IND Development for CAR-T Cell Therapy
    • 14.27.12. GMP Production for CAR-T Products
    • 14.27.13. CAR-T Clinical Trial Services
  • 14.28. CRISPR Therapeutics
    • 14.28.1. CRISPR Therapeutics' Immuno-Oncology Programs
    • 14.28.2. CRISPR/Cas9-enabled Allogeneic CAR-T Design
  • 14.29. Curocell, Inc.
    • 14.29.1. OVIS Technology
  • 14.30. DiaCarta
    • 14.30.1. Personalized CAR-T Immunotherapy Platform
  • 14.31. Elicera Therapeutics AB
    • 14.31.1. iTANK CAR-T Technology
    • 14.31.2. Elicera's Product Pipeline
  • 14.32. EXUMA Biotech
    • 14.32.1. TMR CAR-T Technology
    • 14.32.2. CCT3 CAR-T
    • 14.32.3. rPOC SC CAR-TaNKs
    • 14.32.4. GCAR "in vivo Cell Therapy"
  • 14.33. Fate Therapeutics
    • 14.33.1. FT819
    • 14.33.2. FT825
  • 14.34. Galapagos NV
  • 14.35. Gilead Sciences, Inc.
    • 14.35.1. CAR-T Products
      • 14.35.1.1. Tecartus (brexucabtagene autoleucel)
      • 14.34.1.2. Yescarta (axicabtagene ciloleucel)
  • 14.36. Gracell Biotechnologies
    • 14.36.1. FasTCAR
    • 14.36.2. TruUCAR
    • 14.36.3. SMART CAR-T
    • 14.36.4. Gracell's Product Pipeline
  • 14.37. IASO Biotherapeutics
    • 14.37.1. Technology Platforms
    • 14.37.2. Fully Human Antibody Discovery Platform
    • 14.37.3. High-Throughput Screening Platform for CAR-T Candidates
    • 14.37.4. Universal CAR-T Technology Platform
    • 14.37.5. CAR-T Manufacturing Technology Platform
    • 14.37.6. IASO's Diverse Product Pipeline
  • 14.38. ImmPACT Bio
    • 14.38.1. CD19/20 Bispecific CAR
    • 14.38.2. TGF-Beta
  • 14.39. Immuneel Therapeutics, Pvt., Ltd.
    • 14.39.1. Immuneel's R&D Roadmap
  • 14.40. ImmunoACT
    • 14.40.1. NexCAR19 (Actalycabtagene autoleucel)
  • 14.41. Interius BioTherapeutics
    • 14.41.1. Core Technology
  • 14.42. Juventas Cell Therapy
    • 14.42.1. Yuanruida (inaticabtagene autoleucel)
  • 14.43. JW Therapeutics
    • 14.43.1. Carteyva (relmacabtagene autoleucel; relma-cel)
  • 14.44. Kite Pharma (Gilead)
    • 14.44.1. Kite's Marketed CAR-T Products
      • 14.44.1.1. Yescarta (axicabtagene ciloleucel)
      • 14.44.1.2. Tecartus (brexucabtagene autoleucel)
    • 14.44.2. Kite's Pipeline Cancer Therapies
  • 14.45. Kyverna Therapeutics
    • 14.45.1. Kyverna's CAR-T Therapy for Autoimmune Diseases
  • 14.46. Legend Biotech
    • 14.46.1. Technology Platforms
      • 14.46.1.1. CAR-T
      • 14.46.1.2. CAR-Gamma-Delta T
      • 14.46.1.3. CAR-NK
      • 14.46.1.4. Non-Gene-Editing Universal CAR-T
    • 14.46.2. Product Pipeline
  • 14.47. Leucid Bio
    • 14.47.1. Leucid's Lateral CAR-Platform
    • 14.47.2. LEU011 - NKG2D CAR-T Cell Therapy
    • 14.47.3. T2, Gamma-Delta T-Cells for Off-The-Shelf Therapy
    • 14.47.4. T4 Immunotherapy
    • 14.47.5. Novel Manufacturing Platform
  • 14.48. Luminary Therapeutics, Inc.
    • 14.48.1. Allogeneic Gamma 2.0+ Platform
    • 14.48.2. Non-Viral Gene Modification Process
    • 14.48.3. Split Co-Stim Dual CAR
    • 14.48.4. Ligand-Based CAR to Target Three Antigens
    • 14.48.5. Product Pipeline
  • 14.49. Lyell Immunopharma, Inc.
    • 14.49.1. Technology
      • 14.49.1.1. Gen-R Technology
      • 14.49.1.2. Epi-R Technology
    • 14.49.2. Lyell's Product Pipeline
  • 14.50. March Biosciences
    • 14.50.1. MB-105
    • 14.50.2. March Biosciences' Pipeline
  • 14.51. MaxCyte, Inc.
    • 14.51.1. Technology: Flow Electroporation
    • 14.51.2. MaxCyte's Electroporation Systems
      • 14.51.2.1. ATx
      • 14.51.2.2. GTx
      • 14.51.2.3. STx
      • 14.51.2.4. VLx
  • 14.52. Minerva Biotechnologies Corporation
    • 14.52.1. CAR-T (huMNC2-CAR44)
  • 14.53. Mustang Bio
    • 14.53.1. Mustang's CAR-T Focus
  • 14.54. Noile-Immune Biotech
    • 14.54.1. PRIME CAR-T
  • 14.55. Novartis AG
    • 14.55.1. The Pioneer in CAR-T
    • 14.55.2. Kymriah (tisagenlecleucel)
    • 14.55.3. T-Charge Platform
      • 14.55.3.1. Phase I YTB323 Clinical Study
      • 14.55.3.2. Phase I PHE 885 Clinical Study
  • 14.56. Oncternal Therapeutics
    • 14.56.1. ONCT-808
  • 14.57. Oxford Biomedica plc
    • 14.57.1. LentiVector Platform
    • 14.57.2. inAAVate Platform
    • 14.57.3. CDMO Services
  • 14.58. PeproMene Bio, Inc.
    • 14.58.1. BAFFR CAR-T Cells
  • 14.59. Poseida Therapeutics, Inc.
    • 14.59.1. Poseida's Genetic Engineering Platforms
    • 14.59.2. PiggyBac Platform for Insertion
    • 14.59.3. Cas-CLOVER Platform for Editing
    • 14.59.4. Poseida's CAR-T Product Candidates
  • 14.60. Precigen, Inc.
    • 14.60.1. UltraCAR-T
    • 14.60.2. Sleeping Beauty System
    • 14.60.3. UltraPorator System
    • 14.60.4. Product Pipeline
  • 14.61. Prescient Therapeutics
    • 14.61.1. OmniCAR
    • 14.61.2. CellPryme
  • 14.62. ProMab Biotechnologies, Inc.
    • 14.62.1. ProMab's CAR-T Cells
    • 14.62.2. ProMab's Services
    • 14.62.3. ProMab's Preclinical and Clinical Study Services
  • 14.63. SOTIO Biotech BV
    • 14.63.1. BOXR Technology
    • 14.63.2. BOXR1030
  • 14.64. Syngene International, Ltd.
    • 14.64.1. CAR-T Services
  • 14.65. Synthekine
    • 14.65.1. STK-009 + SYNCAR-001
  • 14.66. TC BioPharm
    • 14.66.1. Gamma Delta T Cells
    • 14.66.2. Cell Banks
    • 14.66.3. Co-Stim CAR-T
    • 14.66.4. Product Pipeline
      • 14.66.4.1. OmnImmune
    • 14.66.5. CAR-T Programs
  • 14.67. T-CURX
    • 14.67.1. Technologies
  • 14.68. Umoja Biopharma
    • 14.68.1. Umoja's Technology Platforms
      • 14.68.1.1. VivoVec in vivo Gene Delivery
      • 14.68.1.2. RACR-Induced Cytotoxic Lymphocytes (iCIL)
      • 14.68.1.3. RACR/CAR: in vivo Cell Programming
      • 14.68.1.4. TumorTag: Universal CAR Tumor Targeting
  • 14.69. ViTToria Biotherapeutics
    • 14.69.1. Senza5
    • 14.69.2. VIPER-101
  • 14.70. Vor Biopharma
    • 14.70.1. Vor Biopharma's Approach
  • 14.71. Wugen
  • 14.72. WuXi Advanced Therapies
    • 14.72.1. WuXi's Closed Process CAR-T manufacturing
  • 14.73. Xenetic Biosciences
    • 14.73.1. DNase-based Oncology Platform
  • 14.74. Xyphos Biosciences, Inc.
    • 14.74.1. ACCEL & UDC Technology
    • 14.74.2. convertibleCAR
    • 14.74.3. Universal Donor Cells

INDEX OF FIGURES

  • FIGURE 2.1: The Basic Structure of a T cell
  • FIGURE 2.2: Binding of a T cell on to an Infected Cell
  • FIGURE 2.3: Components of a CAR-T cell
  • FIGURE 2.4: The Three Domains of a CAR
  • FIGURE 2.5: The first Generation CARs
  • FIGURE 2.6: Second Generation CARs
  • FIGURE 2.7: Third Generation CARs
  • FIGURE 2.8: Fourth Generation CARs
  • FIGURE 2.9: Fifth Generation CARs
  • FIGURE 2.10: CAR Constructs in the FDA Approved CAR-T Cell Products
  • FIGURE 2.11: Antigens Present on Normal and Cancer Cells
  • FIGURE 2.12: Preparation and Administration of CAR-T cell Therapy
  • FIGURE 2.13: Kymriah in Infusion Bag
  • FIGURE 2.14: Yescarta in Infusion Bag
  • FIGURE 2.15: Tecartus in Infusion Bag
  • FIGURE 2.16: Carvykti in Infusion Bag
  • FIGURE 2.17: Abecma in the Infusion Bag
  • FIGURE 2.18: Breyanzi in Package
  • FIGURE 2.19: Relma-cel Infusion Bag
  • FIGURE 3.1: Switchable CARs [sCARs; Universal CARs]
  • FIGURE 3.2: Action of Suicide Genes
  • FIGURE 3.3: Graphical Abstract for Transient Transfection
  • FIGURE 3.4: A Model of Armored CAR
  • FIGURE 4.1: The Five Generations of CARs
  • FIGURE 5.1: Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies
  • FIGURE 5.2: G-Rex Bioreactors
  • FIGURE 5.3: CliniMACS Prodigy
  • FIGURE 5.4: Scaling Up of Allogeneic CAR-T Cells
  • FIGURE 5.5: Operating Expenses in Autologous CAR-T Manufacturing
  • FIGURE 5.6: Operating Expenses in Allogeneic CAR-T Manufacturing
  • FIGURE 6.1: CAR-T Target Antigens Evaluated in Clinical Trials
  • FIGURE 7.1: Number of CAR-T Patents Filed from 2000 to March 2024
  • FIGURE 8.1: CAR-T Clinical Trials by Phase of Study, March 2024
  • FIGURE 8.2: Types of Hematological Malignancies Addressed in Clinical Trials
  • FIGURE 8.3: Studies for Simultaneous Targets by One CAR-T
  • FIGURE 8.4: CAR-T Generation Types used in Clinical Trials
  • FIGURE 8.5: Distribution of CAR-T Trials by Type of SeFv Used
  • FIGURE 8.6: Distribution of CAR-T Trials by Type of Vectors Used
  • FIGURE 8.7: Solid Tumor Types in Clinical Trials, March 2024
  • FIGURE 8.8: Liquid Cancers vs. Solid Cancers in CAR-T Clinical Trials
  • FIGURE 9.1: Number of Published CAR-T Papers on PubMed.gov, 2000-March 2024
  • FIGURE 9.2: PubMed. Papers on Autologous vs. Allogeneic CAR-T Therapies, 2000-2024
  • FIGURE 9.3: PubMed Papers on CAR-T for Liquid vs. Solid Cancers, 2013-March 2024
  • FIGURE 9.4: PubMed Papers on the Five Generation of CARs
  • FIGURE 10.1: Venture Capital Funding for CAR-T Companies by Year, 2014-March 2024
  • FIGURE 10.2: IPO Invested in CAR-T Companies, 2014-March 2024
  • FIGURE 13.1: Uptake of CAR-T Doses, 2017-2023
  • FIGURE 13.2: Revenue Generation by CAR-T Therapy by Product, 2017-2023
  • FIGURE 13.3: Estimated Modest Growth of CAR-T Market by Product, 2023-2032
  • FIGURE 13.4: Global Market for CAR-T Products by Geography, 2023-2032
  • FIGURE 13.5: Global Market for CAR-T Therapies by Indication, 2024-2032
  • FIGURE 14.1: Atara's Approach to Allogeneic Cell Therapy
  • FIGURE 14.2: Illustration of CycloCAR-T
  • FIGURE 14.3: Illustration of THANK-uCAR-T
  • FIGURE 14.5: Schematic of Allogeneic P CAR-T with TCR KO
  • FIGURE 14.6: NKG2D-based CAR
  • FIGURE 14.7: Celyad's Multispecific CAR
  • FIGURE 14.8: CRISPR/Cas9-enabled Allogeneic CAR-T Design
  • FIGURE 14.9: FT819
  • FIGURE 14.10: FT825
  • FIGURE 14.11: FasTCAR vs. Conventional CAR-T Manufacturing Time
  • FIGURE 14.12: Action of TruUCAR
  • FIGURE 14.13: SMART CAR-T
  • FIGURE 14.14: CD19/CD20 CAR-T Technology
  • FIGURE 14.15: TGF-Beta Bispecific CAR Technology
  • FIGURE 14.16: Lateral CAR
  • FIGURE 14.17: T4 T-Cell
  • FIGURE 14.18: Split Co-Stim Dual CAR
  • FIGURE 14.19: Ligand-Based CAR to Target Three Antigens
  • FIGURE 14.20: Natural Killing of CAR-T Cells
  • FIGURE 14.21: ATx
  • FIGURE 14.22: GTx
  • FIGURE 14.23: STx
  • FIGURE 14.24: VLx
  • FIGURE 14.25: Features of PRIME CAR-T Cell Therapy
  • FIGURE 14.26: BAFFR CAR-T Cells
  • FIGURE 14.27: Poseida's PiggyBac Platform for Insertion
  • FIGURE 14.28: Poseida's Cas-CLOVER Platform for Editing
  • FIGURE 14.29: UltraCAR-T Cell
  • FIGURE 14.30: Precigen's Ultraporator System
  • FIGURE 14.31: Prescient's OmniCAR
  • FIGURE 14.32: VIPER-101, the Lead Program of ViTToria
  • FIGURE 14.33: WuXi's Closed Process CAR-T Platform
  • FIGURE 14.34: Convertible CAR Parts
  • FIGURE 14.35: Xyphos' Universal Donor Cells
  • INDEX OF TABLES
  • TABLE 2.1: Potential CAR-T Targeted Antigens Present on Hematological Malignant Cells
  • TABLE 2.2: Key Differences between the Available Vectors
  • TABLE 2.3: The Eight CAR-T Cell Therapies Available in the Market
  • TABLE 2.4: Toxicities Associated with CAR-T Treatment
  • TABLE 3.1: Strategies for Future CAR-T Therapies
  • TABLE 3.2: A Sample of CAR-T Studies on Solid Tumors
  • TABLE 3.3: New Target Antigens and New Target Cancers
  • TABLE 3.4: A sample of Allogeneic CAR-T Studies
  • TABLE 4.1: History of Development of CAR-T Cell Therapy
  • TABLE 4.2: Approved CAR-T Products, their Developers and Indications
  • TABLE 4.3: Upcoming CAR-T Stars
  • TABLE 4.4: Cancer Population Addresses by CAR-T Therapy
  • TABLE 6.1: CAR-T Target Antigens in Hematological Cancers
  • TABLE 6.2: Targeted Antigens involved in the Approved CAR-Ts
  • TABLE 7.1: Geographical Distribution of CAR-T Patents, March 2024
  • TABLE 7.2: Top Ten Applicants for CAR-T Patents, March 2024
  • TABLE 7.3: Top Ten Inventors of CAR-T Patents, March 2024
  • TABLE 7.4: Top Ten Owners of CAR-T Patents, March 2024
  • TABLE 7.5: Legal Status of CAR-T Patent Applications, March 2024
  • TABLE 8.1: CAR-T Clinical Trials by Country, March 2024
  • TABLE 8.2: Number of CAR-T Clinical Trials by Funding Type, March 2024
  • TABLE 8.3: Clinical Trials Focusing on Solid Tumors by Country, March 2024
  • TABLE 8.4: CAR-T Solid Tumor Clinical Trials by Phase of Study, March 2024
  • TABLE 8.5: Funding Types in CAR-T Solid Tumor Clinical Trials, March 2024
  • TABLE 8.6: Percent Biomarker Distribution in CAR-T Clinical Trials
  • TABLE 8.7: CAR-T Targeted Indications in the U.S. Clinical Trials
  • TABLE 8.8: Indications Addressed by CAR-T Clinical Trials in China
  • TABLE 8.9: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
  • TABLE 8.10: CAR-T Clinical Trial Sponsor Companies and Institutions in China
  • TABLE 8.11: CAR-T Clinical Trial Sponsor Companies and Institutions in Other Countries
  • TABLE 8.12: Clinical Trials of 4th, 5th gen. and Gene Edited CAR-Ts
  • TABLE 9.1: NIH Funding for CAR-T Research, 2024
  • TABLE 10.1: CAR-T Venture Capital Funding, 2014-March 2024
  • TABLE 10.2: IPO Invested in CAR-T Companies, 2014-March 2024
  • TABLE 10.3: CAR-T Licensing Deals, 2015-March 2024
  • TABLE 10.4: CAR-T Collaboration Deals Signed between 2013 and March 2024
  • TABLE 10.5: CAR-T Merger and Acquisition (M&A) Deals, 2015-March 2024
  • TABLE 10.6: Overview of CAR-T Funding, 2014-March 2024
  • TABLE 11.1: List Prices of CAR-T Cells
  • TABLE 11.2: Pre-, Peri-, and Post Infusion Unit Costs
  • TABLE 11.3: Adverse Events Rates and Unit Costs of Management
  • TABLE 11.4: Reimbursement for CAR-T Cases, FY 2023 vs. FY 2024
  • TABLE 11.5: Cost of CAR-T cell Products in the EU Countries
  • TABLE 11.6: Cost Components and Resource Use of Pre- and Post- CAR-T Cell Therapy
  • TABLE 11.7: Average Total Costs Pre- and Post- CAR-T Treatment in Former EU 5 and NL
  • TABLE 11.8: CAR-T Reimbursement Schemes in Europe
  • TABLE 12.1: FDA-Approved Therapies for R/R ALL Pediatric and Young Adult Patients
  • TABLE 12.2: FDA Approved Therapies for DLBCL
  • TABLE 12.3: FDA Approved Therapies for MCL
  • TABLE 12.4: FDA Approved Drugs for Multiple Myeloma
  • TABLE 12.5: FDA-Approved Drugs for Follicular Lymphoma
  • TABLE 12.6: Cost of Treating Blood Cancers
  • TABLE 13.1: Uptake of CAR-T Doses, 2017-2023
  • TABLE 13.2: Revenue Generation by CAR-T Therapy by Product, 2017-2023
  • TABLE 13.3: Estimated Modest Growth of CAR-T Cell Market by Product, 2023-2032
  • TABLE 13.4: Global Market for CAR-T Products by Geography, 2023-2032
  • TABLE 13.5: Global Market for CAR-T Therapies by Indication, 2024-2032
  • TABLE 14.1: AffyImmune's Affinity-Tuned Pipeline Products
  • TABLE 14.2: Aleta's CAR-T Engager Pipeline
  • TABLE 14.3: Allogene's AlloCAR-T Pipeline
  • TABLE 14.4: Anixa's CAR-T Pipeline
  • TABLE 14.5: Arbele's Advanced Cell Therapy Product Candidates
  • TABLE 14.6: ArcellX's Current Product Pipeline
  • TABLE 14.7: Atara's Product Pipeline
  • TABLE 14.8: Autolus' Therapies in Development
  • TABLE 14.9: Clinical & Preclinical Pipeline Overview
  • TABLE 14.10: Bellicum's Pipeline
  • TABLE 14.11: BRiDGECAR Program
  • TABLE 14.12: Cabaletta's Autoimmune Therapy Candidates in Development
  • TABLE 14.13: Carina's Clinical Programs
  • TABLE 14.14: CARsgen's Product Pipeline
  • TABLE 14.15: Cartesian's Product Pipeline
  • TABLE 14.16: Cellectis' Allogeneic CAR-T Cell Product Pipeline
  • TABLE 14.17: CRISPR Therapeutics' CAR-T Programs
  • TABLE 14.18: Elicera's Product Pipeline
  • TABLE 14.19: EXUMA's Pipeline Assets
  • TABLE 14.20: Galapagos' Oncology CAR-T Pipeline
  • TABLE 14.21: Gracell's Rich Product Pipeline
  • TABLE 14.22: IASO's Diverse Product Pipeline
  • TABLE 14.23: ImmPACT Bio's Product Pipeline
  • TABLE 14.24: Immuneels Product Pipeline
  • TABLE 14.25: JW Therapeutics' Product Pipeline
  • TABLE 14.26: Kite's Pipeline Cancer Therapies
  • TABLE 14.27: Product Pipeline to address Autoimmune Diseases
  • TABLE 14.28: Legend Biotech's Product Pipeline
  • TABLE 14.29: Leucid's Product Pipeline
  • TABLE 14.30: Luminary's Product Pipeline
  • TABLE 14.31: Lyell's Product Pipeline
  • TABLE 14.32: March Biosciences' Product Pipeline
  • TABLE 14.33: A Comparison Guide for MaxCyte's Elecroporation Systems
  • TABLE 14.34: Minerva's CAR-T Pipeline Products for Solid Tumors
  • TABLE 14.35: Mustang's CAR-T Product Candidates
  • TABLE 14.36: Noile-Immune's PRIME-Based Product Pipeline
  • TABLE 14.37: Oxford Biomedica's CDMO Services
  • TABLE 14.38: PeproMene's Product Pipeline
  • TABLE 14.39: Poseida's CAR-T Product Pipeline
  • TABLE 14.40: Precigen's UltraCAR-T Pipeline
  • TABLE 14.41: Prescient's CAR-T Pruct Pipeline
  • TABLE 14.42: ProMabs CAR-T Cells
  • TABLE 14.43: ProMab's Discovery Services Plans & Prices
  • TABLE 14.44: Synthekine's Pipeline with SYNCAR-001 + STK-009
  • TABLE 14.45: T-CURX' Product Candidates in Clinical Trials
  • TABLE 14.46: Umoja's Product Pipeline
  • TABLE 14.47: Vor Biopharma's Current Product Pipeline
  • TABLE 14.48: Wugen's Product Pipeline
  • TABLE 14.49: Xenetic's CAR-T Product Pipeline